A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia

The clinical trial met its primary objective of demonstrating an acceptable safety profile for SANGUINATE in patients with sickle cell anemia. This trial established the safety of SANGUINATE at both dose levels and permitted its advance to Phase II trials.